An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): Incorporating a systematic review, metaanalysis and value of information analysis

Health Technology Assessment

Volumn 16, Issue 7, 2012, Pages

  Soares, M O ^a   Welton, N J ^b   Harrison, D A ^c   Peura, P ^a   Hari, M S ^d   Harvey, S E ^c   Madan, J J ^b   Ades, A E ^b   Palmer, S J ^a   Rowan, K M ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c and London School of Hygiene Tropical Medicine   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; FEASIBILITY STUDY; HUMAN; INFORMATION SYSTEM; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SEPTIC SHOCK; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT DURATION; UNITED KINGDOM;

EID: 84857879859     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta16070     Document Type: Article

References (122)

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/ SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
2. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D. et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-6.
3. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006;10:R42.
4. Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004;8:222-6.
5. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003;31:2332-8.
6. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005;142:1-11.
7. Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002;107:387-93.
8. Wallington T. New uses for IVIgG immunoglobulin therapies. Vox Sang 2004;87:155-7.
9. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002;1:CD001090.
10. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007;35:2677-85.
11. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007;35:2686-92.
12. Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, et al. Metaanalysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007;146:193-203.
13. Norrby-Teglund A, Haque KN, Hammarstrom L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med 2006;260:509-16.
14. Pildal J, Gøtzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004;39:38-46.
15. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock (review). Cochrane Library 2010;(2).
16. Department of Health. Demand Management Plan for Immunoglobulin Use. 2nd edn. London: Department of Health; 2008.
17. Department of Health. Clinical Guidelines for Immunoglobulin Use. 2nd edn. London: Department of Health; 2008.
18. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
19. Levy MM, Pronovost PJ, Dellinger RP, Townsend S, Resar RK, Clemmer TP, et al. Sepsis change bundles: converting guidelines into meaningful change in behavior and clinical outcome. Crit Care Med 2004;32:S595-7.
20. Surving Sepsis Campain. Severe sepsis bundles. URL: www.survivingsepsis.com/node/89 (accessed 18 August 2010).
21. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.
22. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
23. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97.
24. Survive sepsis. URL: www.survivesepsis.org.uk (accessed 18 August 2010).
25. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized trials: is blinding necessary? Control Clin Trials 1996;17:12.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
27. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63.
28. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
29. Elebute EA, Stoner HB. The grading of sepsis. Br J Surg 1983;70:29-31.
30. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
31. Higgins JPT, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med 1996;15:2733-49.
32. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900.
33. Ades AE, Sculpher M, Sutton A, Abrams K, Copper N, Welton NJ, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics, PharmacoEcon 2006;24:1-19.
34. Ades A, Welton N, Lu G. Introduction to mixed treatment comparisons. 2005. URL: www. bris.ac.uk/cobm/research/mpes/mtc.html (accessed 17 October 2011).
35. Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: evolution, critique and future directions. Stat Med 2009;28:3049-67.
36. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37.
37. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B 2002;64:583-616.
38. Vogel F, Exner M, Franke P, Gien C. Nosokomiale sepsis. In: Deicher H, Schoppe W, editors. Klinisch angewandte immunologie-sepsis therapie mit IgM-angereichertem immunoglobulin. Berlin: Springer-Verlag; 1988. pp.30-41.
39. Dominioni L, Dionigi R, Zanello M, Chiaranda M, Dionigi R, Acquarolo A, et al. Effects of high-dose IgG on survival of surgical patients with sepsis scored of 20 or greater. Arch Surg 1991;126:236-40.
40. Just H-M, Metzger M, Vogel W, Penack O. Einfluss einer adjuvanten immunglobulintherapie auf infektionen bei patienten einer operativen intensiv-therapie-station. Klin Wochenschr 1986;64:245-56.
41. Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J. Cooperative group of additional immuinoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinpurulent peritonitis. Klin Wochenschr 1987;65:1132-8.
42. Rodriguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 2005;23:298-304.
43. Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 2006;34:1319-25.
44. Karatzas S, Boutzouka E, Venetsanou K, Myrianthefs P, Fildisis G, Baltopoulos G. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view. Crit Care 2002;6:543-4.
45. Tugrul S, Ozcan PE, Akinci O, Seyhun Y, Cagatay A, Cakar N, et al. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis. Crit Care 2002;6:357-62.
46. Behre G, Ostermann H, Schedel I, Helmerking M, Schiel X, Rothenburger M, et al. Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: pilot study and interim analysis of a randomized trial. Anti Infect Drugs Chemother1995;13:129-34.
47. Schedel I, Dreikhausen U, Nentwig B, Hockenschnieder M, Rauthmann D, Balikcioglu S, et al. Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 1991;19:1104-13.
48. Wesoly C, Kipping N, Grundmann R. Immunglobulintherapie der postoperativen sepsis. Z Exp Chir Transplant Kunstliche Organe 1990;23:213-16.
49. Spannbrucker N, Munch HG, Kunze R, Vogel F. Auswirkungen von immunglobulinsubstitution bei sepsis. Intensivmedizin 1987;6:314.
50. Dominioni L, Bianchi V, Imperatori A, Minoia G, Dionigi R, Abakumov MM. High-dose intravenous IgG for treatment of severe surgical infections. Dig Surg 1996;13:430-4.
51. Burns ER, Lee V, Rubinstein A. Treatment of septic thrombocytopenia with immune globulin. J Clin Immunol 1991;11:363-8.
52. De Simone C, Delogu G, Corbetta G. Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Crit Care Med 1988;16:23-6.
53. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007;35:2693-701.
54. Grundmann R, Hornung M. Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis-a prospective randomized study. Prog Clin Biol Res 1988;272:339-49.
55. Yakut M, Cetiner S, Akin A, Tan A, Kaymakcioglu N, Simsek A, et al. Sepsisdeki hastalarda immunglobulin G (IgG) kullaniminin mortalite oranina etkisi. GATA Bulteni 1998;40:76-81.
56. Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333-40.
57. Lindquist L, Lundbergh P, Maasing R. Pepsin-treated human gamma globulin in bacterial infections: a randomized study in patients with septicaemia and pneumonia. Vox Sang 1981;40:329-37.
58. Masaoka T, Hasegawa H, Takaku F. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Jpn J Chemother 2000;48:199-217.
59. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC, French Guillain-Barré Syndrome Cooperative G. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001;71:235-8.
60. Tugrul S, Ozcan PE, Akinci O, Cagatay A, Cakar N, Esen F. [The effect of pentaglobin therapy on prognosis in patients with severe sepsis]. Ulus Travma Derg 2001;7:219-23.
61. Bellomo R, Uchino S, Naka T, Wan L. Hidden evidence to the West: multicentre, randomised, controlled trials in sepsis and systemic inflammatory response syndrome in Japanese journals. Intensive Care Med 2004;30:911-17.
62. Reith HB, Rauchschwalbe SK, Mittelkotter U, Engemann R, Thiede A, Arnold A, et al. IgMenriched immunoglobulin (pentaglobin) positively influences the course of post-surgical intra-abdominal infections. Eur J Med Res 2004;9:479-84.
63. Buda S, Riefolo A, Biscione R, Goretti E, Cattabriga I, Grillone G, et al. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery. J Cardiothorac Vasc Anesth 2005;19:440-5.
64. Khan S, Sewell WAC. Risks of intravenous immunoglobulin in sepsis affect trial design. Ann Intern Med 2007;147:813.
65. Calandra T, Glauser MP, Schellekens J, Verhoef J, Swiss-Dutch J5 Immunoglobulin Study Group. Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind randomized trial. J Infect Dis 1988;158:312-19.
66. Pilz G, Appel R, Kreuzer E, Werdan K. Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk of sepsis. Chest 1997;111:419-26.
67. Keane W, Hirata-Dulas CAI, Bullock ML, Ney AL, Guay DRP, Kalil RSN, et al. Adjunctive therapy with intravenous human immunoglobulin G improved survival of patients with acute renal failure. J Am Soc Nephrol 1991;2:841-7.
68. Vincent J-L, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med 2004;32:2029-38.
69. Moreno SG, Sutton AJ, Ades AE, Stanley TD, Abrams KR, Peters JL, et al. Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Med Res Methodol 2009;9: 2.
70. Moreno SG, Sutton AJ, Turner EH, Abrams KR, Cooper NJ, Palmer TM, et al. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. BMJ 2009;339:b2981.
71. Werdan K. Mirror, mirror on the wall, which is the fairest meta-analysis of all? Crit Care Med 2007;35:2852-4.
72. Drummond MF. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press; 2005.
73. Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care 2005;20:239-49.
74. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002;347:993-1000.
75. Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, et al. Costeffectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003;31:1-11.
76. Betancourt M, McKinnon PS, Massanari RM, Kanji S, Bach D, Devlin JW. An evaluation of the cost effectiveness of drotrecogin alfa (Activated) relative to the number of organ system failures. PharmacoEconomics 2003;21:1331-40.
77. Fowler RA, Hill-Popper M, Stasinos J, Petrou C, Sanders GD, Garber AM. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 2003;18:181-91.
78. Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 2003;18:217-27.
79. Sacristán JA, Prieto L, Huete T, Artigas A, Badia X, Chinn C, et al. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain]. Gac Sanit 2004;18:50-7.
80. Davies A, Ridley S, Hutton J, Chinn C, Barber B, Angus DC. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Anaesthesia 2005;60:155-62.
81. Hjelmgren J, Persson U, Tennvall GR. Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden. Am J Ther 2005;12:425-30.
82. Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, et al. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technol Assess 2005;9(11).
83. Green C, Dinnes J, Takeda AL, Cuthbertson BH. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Int J Technol Assess Health Care 2006;22:90-100.
84. Franca LR, Launois R, Le Lay K, Aegerter P, Bouhassira M, Meshaka P, et al. Costeffectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. Int J Technol Assess Health Care 2006;22:101-8.
85. Dhainaut JF, Payet S, Vallet B, Franca L, Annane D, Bollaert PE, et al. Cost-effectiveness of activated protein C in real-life clinical practice. Crit Care 2007;11:R99.
86. Costa V, Brophy JM. Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. BMC Anaesthesiol 2007;7:5.
87. Guidet B, Mosqueda GJ, Priol G, Aegerter P. The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock. J Crit Care 2007;22:197-203.
88. Huang DT, Clermont G, Dremsizov TT, Angus DC. Implementation of early goaldirected therapy for severe sepsis and septic shock: a decision analysis. Crit Care Med 2007;35:2090-100.
89. Talmor D, Greenberg D, Howell MD, Lisbon A, Novack V, Shapiro N. The costs and costeffectiveness of an integrated sepsis treatment protocol. Crit Care Med 2008;36:1168-74.
90. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2001;2:CD001090.
91. Briggs A, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
92. Bernard GR, Vincent JL, Laterre P, Larosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
93. Quartin AA, Schein RMH, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. JAMA 1997;277:1058-63.
94. Wright JC, Plenderleith L, Ridley SA. Long-term survival following intensive care: subgroup analysis and comparison with the general population. Anaesthesia 2003;58:637-42.
95. Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004;32:2199-206.
96. Drabinski A, Williams G, Formica C. Observational evaluation of health state utilities. Value Health 2001;4:130.
97. Angus DC, Musthafa AA, Clermont G, Griffin MF, Linde-Zwirble WT, Dremsizov TT, et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;163:1389-94.
98. URL: www.icapp.nhs.uk/docdat/ (accessed 18 August 2010).
99. Harrison DA, Brady AR, Rowan K. Case mix, outcome and length of stay for admissions to adult, general critical-care units in England, Wales and Northern Ireland: the Intensive Care National Audit & Research Centre Case Mix Programme Database. Crit Care 2004;8:R99-111.
100. Harrison DA, Parry GJ, Carpenter JR, Short A, Rowan K. A new risk prediction model for critical care: the Intensive Care National Audit & Research Centre (ICNARC) model. Crit Care Med 2007;35:1091-8.
101. Williams TA, Dobb GJ, Finn JC, Webb SAR. Long-term survival from intensive care: a review. Intensive Care Med 2005;31:1306-15.
102. Ghelani D, Moran JL, Sloggett A, Leeson RJ, Peake SL. Long-term survival of intensive care and hospital patient cohorts compared with the general Australian population: a relative survival approach. J Eval Clin Pract 2009;15:425-35.
103. Karlsson S, Varpula M, Ruokonen E, Pettila V, Parviainen I, Ala-Kokko TI, et al. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 2007;33:435-43.
104. Varpula M, Karlsson S, Parviainen I, Ruokonen E. Community-acquired septic shock: early management and outcome in a nationwide study in Finland. Acta Anaesthesiol Scand 2007;51:1320-6.
105. Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G. Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med 2003;31:2316-23.
106. Leibovici L, Samra Z, Konigsberger H, Drucker M, Ashkenazi S, Pitlik SD. Long-term survival following bacteremia or fungemia. JAMA 1995;274:807-12.
107. Perl TM, Dvorak LA, Hwang T, Wenzel RP. Long-term survival and function after suspected Gram-negative sepsis. JAMA 1995;274:338-45.
108. Sasse KC, Nauenberg E, Long A, Anton B, Tucker HJ, Hu TW. Long-term survival after intensive-care unit admission with sepsis. Crit Care Med 1995;23:1040-7.
109. Karlsson S, Ruokonen E, Varpula T, Ala-Kokko TI, Pettila V. Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med 2009;37:1268-74.
110. Granja C, Dias C, Costa-Pereira A, Sarmento A. Quality of life of survivors from severe sepsis and septic shock may be similar to that of others who survive critical illness. Critical Care 2004;8:R91-8.
111. Korošec Jagodic H, Jagodic K, Podbregar M. Long-term outcome and quality of life of patients treated in surgical intensive care: a comparison between sepsis and trauma. Crit Care 2006;10:R134.
112. Williams A. Euroqol-a new facility for the measurement of health-related quality-of-life. Health Policy 1990;16:199-208.
113. National Institute for Health and Clinical Excellence. Guidance to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; 2008.
114. R Development Core Team. The R project for statistical computing. 2010. URL: www.Rproject. org (accessed 17 October 2011).
115. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290-308.
116. Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. Health Technol Assess 2004;8(31).
117. Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Med Decis Making 2004;24:207-27.
118. Claxton K, Posnett J. An economic approach to clinical trial design and research prioritysetting. Health Econ 1996;5:513-24.
119. Cuthbertson BH, Roughton S, Jenkinson D, Maclennan G, Vale L. Quality of life in the five years after intensive care: a cohort study. Crit Care 2010;14:R6.
120. British Medical Association amd Royal Pharmaceutical Society of Great Britain. British national formulary. No. 58, September 2009. London: BMA and RPS; 2009.
121. Department of Health. NHS reference costs 2007/08. URL: www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_098945 (accessed 17 October 2011).
122. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87.